Dose-dependent antihypertensive efficacy and tolerability of perindopril in a large, observational, 12-week, general practice-based study

American Journal of Cardiovascular Drugs

Volumn 11, Issue 1, 2011, Pages 45-55

  Tsoukas, George ^a   Anand, Sanjiv ^b   Yang, Kwang ^c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b Dr Georges L Dumont Regional Hospital   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Hypertension, treatment; Patient compliance; Perindopril, therapeutic use.

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IRBESARTAN; LOSARTAN; PERINDOPRIL; RAMIPRIL; TELMISARTAN; VALSARTAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CANADA; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COUGHING; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GENERAL PRACTICE; GENERAL PRACTITIONER; HEADACHE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; PRURITUS; RACE DIFFERENCE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PERINDOPRIL; PROSPECTIVE STUDIES;

EID: 79251627079     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11587000-000000000-00000     Document Type: Article

References (24)

1. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005 Jan; 365: 217-23
2. Wolf-Maier K, Cooper R, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004 Nov; 43: 10-7
3. Oliveria SA, Lapuerta P, McCarthy BD, et al. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002 Feb; 162: 413-20
4. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42 (6): 1206-52
5. Touyz RM, Canadian Hypertension Education Program (CHEP). Highlights and summary of the 2006 Canadian Hypertension Education Program recommendations. Can J Cardiol 2006 May; 22: 565-71
6. Guo W, Turlapaty P, Shen Y, et al. Clinical experience with perindopril in patients nonresponsive to previous antihypertensive therapy: a large US community trial. Am J Ther 2004 May-Jun; 11: 199-205
7. Julius S, Cohn JN, Neutel J, et al. Antihypertensive utility of perindopril in a large, general practice-based clinical trial. J Clin Hypertens (Greenwich) 2004 Jan; 6: 10-7
8. Ogilvie RI, Anand S, Roy P, et al. Perindopril for control of blood pressure in patients with hypertension and other cardiovascular risk factors: an openlabel, observational, multicentre, general practice-based study. Clin Drug Investig 2008 Sep; 28: 673-86
9. Poggi L, Renucci JF, Denolle T. Treatment of essential hypertension in general practice: an open-label study of 47,351 French hypertensive patients treated for one year with perindopril. Can J Cardiol 1994 Nov; 10 Suppl. D: 21D-4D
10. Physicians Desk Reference. Montvale (NJ): Medical Economics Company, 2010
11. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian CardiacOutcomes Trial-Blood Pressure Lowering Arm(ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 Sep; 366: 895-906
12. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-98
13. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007 Sep; 370: 829-40
14. Bangalore S, Kumar S, Messerli F. Angiotensin-cnverting enzyme inhibitor associated cough: deceptive information from the Physicians Desk Reference. Am J Med 2010 Nov; 123: 1016-30
15. Karpov I, Shalnova SA, Deev AD. Prestarium in patients with arterial hypertension and ischemic heart disease (or risk factors): safe achievement of target blood pressure level (the PREMIERA study). Kardiologiia 2006; 46: 21-7
16. Gasowski J,Wilkins A, Drzewoski J, et al. Short-term antihypertensive efficacy of perindopril according to clinical profile of 3,188 patients: a meta-analysis. Cardiol J 2010; 17: 259-66
17. Johnston C, Fabris B, Yamada H, et al. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens 1989 Sep; 7: S11-6 (Pubitemid 19269331)
18. Bussien JP, dAmore TF, Perret L, et al. Single and repeated dosing of the converting enzyme inhibitor perindopril to normal subjects. Clin Pharmacol Ther 1986 May; 39: 554-8
19. Tropeano AI, Boutouyrie P, Pannier B, et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension 2006 Jul; 48: 80-6
20. Zhuo JL, Mendelsohn FA, Ohishi M. Perindopril alters vascular angiotensinconverting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension 2002; 39: 634-8
21. Ionescu DD. Antihypertensive efficacy of perindopril 5-10mg/day in primary health care: an open-label, prospective, observational study. Clin Drug Investig 2009 Nov; 29: 767-76
22. Telejko E. Perindopril arginine: benefits of a new salt of the ACE inhibitor perindopril. Curr Med Res Opin 2007 May; 23: 953-60
23. Mourad JJ, Bertrand M. Impact of antihypertensive treatment on mortality: a late breaking analysis of recent trials in hypertension. J Hypertens 2010 Jun; 28 Suppl.: 37-495
24. Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008 May; 336: 1114-7